Related Experiment Videos
[A clinical study on cefdinir in pediatric field]
1Department of Pediatrics, Kanto Teishin Hospital.
Insights
Cefdinir (CFDN) demonstrated favorable pharmacokinetics and clinical efficacy in pediatric patients with acute infectious diseases. The antibiotic was well-tolerated, with no adverse reactions reported in the study.
Area of Science:
- Pediatric Infectious Diseases
- Pharmacology
- Clinical Microbiology
Background:
- Acute infectious diseases are common in children.
- Cefdinir is a third-generation cephalosporin antibiotic.
- Understanding cefdinir's profile in pediatric populations is crucial for effective treatment.
Purpose of the Study:
- To evaluate the pharmacokinetic parameters of cefdinir in a pediatric patient.
- To assess the clinical efficacy of cefdinir in children with various acute infectious diseases.
- To determine the safety and tolerability of cefdinir in pediatric use.
Main Methods:
- Pharmacokinetic analysis in a single pediatric subject.
- Clinical efficacy assessment in 11 children diagnosed with acute tonsillitis, scarlet fever, pharyngitis, pneumonia, otitis media, and cervical lymphadenitis.
- Adverse event monitoring throughout the study period.
Main Results:
- Pharmacokinetic parameters in the pediatric subject showed a shorter Tmax, slightly lower Cmax, and a longer plasma half-life compared to adult data.
- Excellent clinical responses were observed in 63.6% of patients, with good responses in 18.2%.
- No adverse reactions were reported during the study.
Conclusions:
- Cefdinir exhibits distinct pharmacokinetic properties in pediatric patients compared to adults.
- Cefdinir demonstrates high clinical efficacy in treating a range of acute infectious diseases in children.
- Cefdinir is safe and well-tolerated in the pediatric population studied.
Abstract:
Cefdinir (CFDN) was administered to pediatric patients with acute infectious disease. A summary of the results obtained is as follows. 1. Pharmacokinetic parameters were determined in a girl. In comparison to reported data in adults, Tmax was shorter, Cmax was slightly lower, and the plasma half life of CFDN was somewhat longer. 2. Clinical efficacy was studied in 11 children with acute tonsillitis (6 patients), scarlet fever (1 patient), acute pharyngitis (1 patient), acute pneumonia (1 patient), acute otitis media (1 patient) and acute cervical lymphadenitis (1 patient). Responses to the treatment were excellent in 7 (63.6%) and good in 2 (18.2%). 3. No adverse reactions were noted in this study.